Differences in Management of Eosinophilic Esophagitis in Europe: An Assessment of Current Practice

J Pediatr Gastroenterol Nutr. 2020 Jul;71(1):83-90. doi: 10.1097/MPG.0000000000002672.


Objectives: The aim of the study was to assess differences in the diagnosis and management of eosinophilic esophagitis (EoE) by European pediatric (PG) and adult gastroenterologists (AG), and their self-reported adherence to guidelines.

Methods: A multiple-choice questionnaire gauged the diagnostic and management strategies of gastroenterologists treating children or adults in 14 European countries and the United Arab Emirates (UAE).

Results: Questionnaires were completed by 465 PG and 743 AG. PG were significantly more likely to take biopsies in patients with symptoms of esophageal dysfunction (86.2% PG vs 75.4% AG, P < 0.001) and to perform endoscopic follow-up (86.3% PG vs 80.6% AG, P < 0.001). After failure of proton-pump inhibitors (PPIs), topical steroids were the preferred second-line therapy; however, PG opted more frequently for elimination diets (47.5% PG vs 13.7% AG, P < 0.001). More PG than AG indicated having read recent guidelines (89.4% PG vs 58.2% AG, P < 0.001). Geographic differences in practice were reported, with respondents from the United Kingdom, Portugal, and Spain more often adhering to recommended biopsy protocols. Physicians in the UAE, France, Lithuania, and Poland tended to opt for steroid therapy or elimination diets as first-line therapy, in contrast to most other countries.

Conclusions: Significant differences in general practice between PG and AG were demonstrated with notable divergence from consensus guidelines. International practice variations are also apparent. Among other strategies, educational activities to highlight current recommendations may help harmonize and optimize clinical practice.

MeSH terms

  • Adult
  • Child
  • Eosinophilic Esophagitis* / diagnosis
  • Eosinophilic Esophagitis* / drug therapy
  • Eosinophilic Esophagitis* / epidemiology
  • Europe
  • France
  • Gastroenterology*
  • Humans
  • Poland
  • Portugal
  • Proton Pump Inhibitors / therapeutic use
  • Spain
  • United Kingdom


  • Proton Pump Inhibitors